Revelation Biosciences Statistics
Want to see REVB full AI Analyst Report?
Revelation Biosciences (REVB) Stock Statistics & Valuation Metrics
Total Valuation
Revelation Biosciences has a market cap or net worth of $2.66M. The enterprise value is -$5.12M.
- Market Cap
- $2.66M
- Enterprise Value
- -$5.12M
Share Statistics
Revelation Biosciences has 683,442 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 683,442
- Owned by Insiders
- 21.51%
- Owned by Institutions
- 0.68%
Financial Efficiency
Revelation Biosciences’s return on equity (ROE) is -1.01 and return on invested capital (ROIC) is -94.41%.
- Return on Equity (ROE)
- -1.01
- Return on Assets (ROA)
- -0.77
- Return on Invested Capital (ROIC)
- -94.41%
- Return on Capital Employed (ROCE)
- -0.95
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.11M
- Employee Count
- 8
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Revelation Biosciences is -0.10. Revelation Biosciences’s PEG ratio is -0.00.
- PE Ratio
- -0.10
- PS Ratio
- 0.00
- PB Ratio
- 0.32
- Price to FCF
- -0.23
- Price to Operating Cash Flow
- -0.23
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, Revelation Biosciences had revenue of 0 and earned -8.91M in profits. Earnings per share was -167.65.
- Revenue
- 0
- Gross Profit
- -27.06K
- Operating Income
- -9.07M
- Pretax Income
- -8.91M
- Net Income
- -8.91M
- EBITDA
- -9.04M
- Earnings Per Share (EPS)
- -167.65
Cash Flow
In the last 12 months, operating cash flow was -10.10M and capital expenditures -111,507, giving a free cash flow of -10.21M billion.
- Operating Cash Flow
- -10.10M
- Free Cash Flow
- -10.21M
- Free Cash Flow per Share
- -18.25
Dividends & Yields
Revelation Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -439.83%
- Earnings Yield
- -532.55%
Stock Price Statistics
- Beta
- 0.52
- 52-Week Price Change
- -86.24%
- 50-Day Moving Average
- 5.44
- 200-Day Moving Average
- 7.42
- Relative Strength Index (RSI)
- 41.78
- Average Volume (3m)
- 11.92K
Important Dates
Revelation Biosciences upcoming earnings date is Apr 01, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Apr 01, 2027
- Ex-Dividend Date
- ―
Financial Position
Revelation Biosciences as a current ratio of 5.41, with Debt / Equity ratio of 8.43%
- Current Ratio
- 5.41
- Quick Ratio
- 5.41
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- 1.10
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Revelation Biosciences has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Revelation Biosciences EV to EBITDA ratio is 0.49, with an EV/FCF ratio of 0.59.
- EV to Sales
- 0.00
- EV to EBITDA
- 0.49
- EV to Free Cash Flow
- 0.59
- EV to Operating Cash Flow
- 0.59
Balance Sheet
Revelation Biosciences has $9.12M in cash and marketable securities with $805.40K in debt, giving a net cash position of $8.32M billion.
- Cash & Marketable Securities
- $9.12M
- Total Debt
- $805.40K
- Net Cash
- $8.32M
- Net Cash Per Share
- $12.17
- Tangible Book Value Per Share
- $12.93
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Revelation Biosciences is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 94.95%
Scores
- Smart Score
- ―
- AI Score
- 43
